No profile data available.
Immix Biopharma, Inc. (IMMX) is a healthcare company in the additional hormone and metabolic drugs industry, based in Los Angeles, United States, with about 21 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$29.44 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $784.26 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. , was incorporated in 2012 and is headquartered in Los Angeles, California.
Immix Biopharma reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$784.26 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Xeris Biopharma Holdings, Inc. (XERS), Eton Pharmaceuticals, Inc. (ETON), MBX Biosciences, Inc. (MBX), Arbutus Biopharma Corporation (ABUS).